Grifola frondosa polysaccharide: a review of antitumor and other biological activity studies in China

Discov Med. 2018 Apr;25(138):159-176.

Abstract

Grifola frondosa, a species of Basidiomycotina, is an edible medicinal mushroom with a large fruiting body characterized by overlapping caps. The β-glucan is the major biologically active component in G. frondosa polysaccharide (GFP) or D-fraction, which has been studied extensively for nearly 30 years. GFP was approved as an adjunctive therapeutic drug in China for treating cancers in 2010. In this article, based on the search results of Chinese VIP, CNKI, and Wanfang databases, 105 independent animal studies were summarized. The chemical structure, the antitumor, immunomodulatory, anti-diabetic, anti-hyperlipidemia, and antiviral activities and molecular mechanisms of GFP are reviewed and discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Antihypertensive Agents* / chemistry
  • Antihypertensive Agents* / therapeutic use
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / therapeutic use
  • China
  • Fungal Polysaccharides* / chemistry
  • Fungal Polysaccharides* / therapeutic use
  • Grifola / chemistry*
  • Humans
  • Hypoglycemic Agents* / chemistry
  • Hypoglycemic Agents* / therapeutic use
  • Immunologic Factors* / chemistry
  • Immunologic Factors* / therapeutic use

Substances

  • Antihypertensive Agents
  • Antineoplastic Agents
  • Fungal Polysaccharides
  • Hypoglycemic Agents
  • Immunologic Factors